IL-10-producing B cells (B10 cells) have been shown to play a suppressive role in the peripheral blood of humans, with their numbers and function altered in several autoimmune diseases. However, the role of B10 cells in Graves' disease (GD) remains unknown. In this study, we demonstrated that B10 cells in human peripheral blood belonged to a CD24 hi CD27 + B cell subpopulation. The proportion of B10 cells along with the CD19 + CD24
Introduction
Graves' disease (GD) is an organ-specific autoimmune disorder characterized by the loss of immunological tolerance, which is pivotal to the appearance of pathogenic autoantibodies against thyroid peroxidase (TPO), thyroglobulin (Tg), and the TSH receptor (TSHR) [1, 2] . This leads to secretion of thyroid hormone with resulting hyperthyroidism and goiters [3] . In some GD patients, intense reactive T and B lymphocytes infiltrate the thyroid and are not effectively suppressed by peripheral tolerance mechanisms [4] . However, the exact etiology of this disease is not well understood, with the consequence that treatment of Graves' disease has not changed over the past 50 years [5] . Immunotherapy until now has included polarization of the Th1/Th2 balance of T-helper cells, targeting regulatory T cells and influencing APC-T cell interactions [6] . However these therapies have only been applied to modify the course of GD in animal models. Recently, clinical trials of a B-lymphocyte depleting monoclonal antibody, anti-CD20 rituximab (RTX), for GD patients have been initiated. B lymphocytes comprise around 9% of lymphocytes in the thyroid gland and in the peripheral blood of GD patients. RTX depletes circulating B lymphocytes efficiently, but the effect is moderate, with only 40% of patients recovering [7, 8, 9] . Moreover, Goetz found disease was exacerbated when RTX was used in patients with ulcerative colitis [10] , and Klaus Lehmann-Horn found out that B cell depletion accentuated pro-inflammatory reaction in neuroimmunological disorders [11] , these findings suggesting that B cells could also have regulatory roles in human blood. We hypothesized that B cell depletion therapy in GD patients eliminated regulatory B cells in peripheral blood, simultaneously resulting in a lower recovery rate. We also postulated that regulatory B cells might be associated with the etiology of GD.
IL-10-producing regulatory B (B10) cells have been identified to play a protective role in murine models of autoimmune diseases, including collagen-induced arthritis (CIA) [12] ,experimental autoimmune encephalomyelitis (EAE) [13] , diabetes [14] , contact hypersensitivity (CHS) [15] , allergic airway inflammation [16] , and intestinal mucosal inflammation [17] . The phenotype and molecular mechanisms of B10 cells in mice have been comprehensively studied. In a murine model of autoimmune disease, the regulatory function of B10 cells observed in ex vivo suppressive assays and in in vivo adoptive transfers was partially IL-10 dependent [18, 19, 20] . Recently, several studies have provided evidence that human B cells can also regulate inflammatory responses. Blair and colleagues found that CD24 hi CD38 hi immature B cell population contained B10 cells that inhibited TNF-a production by CD4 + T cells, and blockade of IL-10 and IL-10R completely reversed their suppressive ability. They also found that CD24 hi CD38 hi B cells were functionally impaired in Systemic Lupus Erythematosus (SLE) patients [21] . In contrast, Iwata et al demonstrated that IL-10-producing B cells were identified as CD24 hi CD27
+ B cells. The frequency of these cells was increased in most autoimmune disease patients. Human B cells can inhibit the function of CD4 + T cells via IL-10-independent pathways [22] . Therefore, the phenotype and immune regulatory mechanisms of IL-10-producing human B cells remain controversial, with more research required to elucidate their phenotype and regulatory mechanisms.
In this study we aimed at identifying the frequency, phenotype and function of B10 cells in healthy individuals and GD patients. We found that ex vivo B10 cells predominantly belonged to the CD24 hi CD27 + B cell subpopulation in GD patients and healthy individuals. The frequency of B10 cells and the CD19 + CD24 hi CD27 + subset was significantly lower in new-onset GD patients compared with that in healthy individuals, while frequencies were similar in healthy individuals and recovered patients. Furthermore, we demonstrated a suppressive function of CD19 + CD24 hi CD27 + cells on CD4 + T cell proliferation, with cytokine production impaired in GD patients.
Results

Enumeration of IL-10-producing B cells in Healthy Individuals and GD Patients
Human blood B10 cells were defined as B cells expressing cytoplasmic IL-10 after 5 h of stimulation with CpG, PMA, ionomycin and BFA. We counted the frequency of B10 cells in total PBMCs and B cells respectively. In new-onset GD patients (n = 15), B10 cells compose 0.36% of total PBMCs and 1.51% of B cells, in recovered GD patients (n = 10), 0.51% of total PBMCs and 2.92% of B cells, and, in healthy individuals (n = 24), 0.64% of total PBMCs and 2.97% of B cells, respectively. (Fig. 1A, B) . The frequency of B10 cells was significantly lower in new-onset GD patients compared with healthy individuals. This frequency in recovered GD patients was increased and close to the level observed in healthy individuals. We also assessed IL-10 transcripts quantification in blood CD19 + B cells. In new-onset GD patients, the levels of these transcripts were 2-3 folds lower than those in healthy individuals and in recovered GD patients. The levels of IL-10 transcripts were similar in recovered patients and healthy individuals (Fig. 1C) .
Phenotypic Characterization of IL-10-competent B cells and Enumeration
As described before, the phenotype of human B10 cells remains ill-defined. Their phenotypic characterization was determined by analyzing cell surface markers (IgM, IgD, CD1d, CD5, CD10, CD20, CD24, CD27, CD38, CD40, CD138 and B220) after in vitro stimulation with CpG and PIB for 5 h. As shown in Fig. 2A and Fig. S1 , blood B10 cells expressed low IgD levels and high CD24 and CD27 levels. The remaining cell surface markers were expressed at similar levels on both IL-10 + B cells and IL-10 2 B cells. As shown in Fig. 2B , blood B10 cells were predominantly found within the CD24 hi CD27 + B cell subset in both healthy individuals and GD patients. There is no much difference in the phenotype of human blood B10 cells between healthy control and GD patients. Representative cell surface phenotypic analysis of IL-10 + or IL-10 2 B cells was picked from one of the healthy individuals in figure 2A 
CD24
hi CD27 + subset composed 1.09% of total PBMCs and 9.68% of B cells, in recovered GD patients (n = 10), 1.64% of total PBMCs and 29.95% of B cells, and in healthy individuals (n = 15), 5.13% of total PBMCs and 30.09% of B cells, respectively. (Fig. 2C, D) .The frequency of the CD19 + CD24 hi CD27 + subset was significantly lower in new-onset GD patients compared with healthy individuals; however, frequencies were increased for recovered GD patients.
CD19
+ Fig. 4A, 5A ), inhibiting the proliferation of CD4 + T cells. The addition of an anti-IL-10 monoclonal antibody did not reverse the inhibition of CD4 + T cells proliferation (Fig. 4B) . The ability of CD19 +
CD24
hi CD27 + B cells to inhibit pro-inflammatory cytokine production in CD4 + T cells was also assessed by flow cytometry. CD4
+ T cells co-cultured with CD19 +
hi CD27 + B cells resulted in significant reduction of IFN-c and TNF-a production (Fig. 4C, D) . IFN-c production was remarkably blocked by anti-IL-10 monoclonal antibody, whereas TNF-a production was not reversed by anti-IL-10 monoclonal antibody in healthy individuals (Fig. 4C, D) .
cells from GD Patients Fail to Suppress CD4
+ cell Proliferation and Cytokine Secretion
Our studies have revealed that the proportion of CD19 + CD24 hi CD27 + B cells was significantly decreased in new-
onset GD patients. This proportion was increased in cured patients, to a level similar to that observed in healthy individuals. We explored the possibility that, in GD disease, this subset of B cells may regulate the proliferation and cytokine production in CD4 + T cells. Interestingly, CD19 + CD24 hi CD27 + B cells from new-onset and recovered GD patients produced less IL-10 compared with healthy individuals (Fig. 5A ). The suppressive effect of CD19 + CD24 hi CD27 + B cells on CD4 + T cell proliferation was significantly impaired in both new-onset and recovered GD patients compared with that in healthy individuals (Fig. 5B) . Additionally, in new-onset and recovered GD patients, the ability of CD19 +
CD24
hi CD27 + B cells to inhibit the production of IFN-c and TNF-a in CD4
+ T cells was also significantly impaired ( Fig. 5C, D 
Discussion
Graves' disease (GD) is an autoimmune disease with deficiencies of immunological tolerance. The frequency and role of regulatory T cells (Tregs) in GD patients remains controversial. Marazuela et al showed that Tregs are deficient and functionally impaired in autoimmune thyroid diseases [4] ; However, in 2009 Pan found that Tregs were not deficient in the peripheral blood of active GD patients and GD patients post-treatment [23] . Thus, further study was needed to determine the reason for the abnormal immune tolerance in GD. It has emerged that a specific IL-10-producing PMA, ionomycin, and CpG, which induced cytoplasmic IL-10 expression and secretion in human B10 cells. This was then able to be easily quantified in vitro [22] . Our combined studies describe that B10 cells were predominantly found within the CD24 hi CD27 + B cell subpopulation. There was a numerical and functional reduction of CD19 + CD24 hi CD27 + B cells in patients with GD. They inhibited proliferation and TNF-a production of CD4 + T cells through IL-10-independent pathways, and inhibited IFN-c through IL-10-dependent pathways in vitro. Therefore, CD19 + CD24 hi CD27 + B cells regulate immune responses partially by secretion of IL-10, and probably via other ways, for instance generate Ag-specific Abs or induced increase in Tregs as describe before [24, 25] .
Our work demonstrated that the frequency of B10 cells, and IL-10 mRNA expression in B cells were significantly lower in new-onset GD patients compared with healthy individuals. The frequencies were increased in recovered patients, to a level similar to that seen in healthy individuals. In contrast Iwata et?al found that the mean B10 cell frequencies in blood were significantly higher in patients with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, autoimmune vesiculobullous skin disease, or multiple sclerosis when compared with healthy individuals [22] . The patients recruited in those studies had been undergoing active treatment with immunomodulatory agents and/or low doses of prednisone, possibly influencing the frequency of B10 cells. Our research has taken into consideration the likely influence of drugs and clinical status, with all new-onset and recovered patients not receiving any anti-thyroid drug treatment. Recovered patients were in a euthyroid state for at least 12 months. Patient cohorts were needed to fully assess the relationship of B10 cell numbers with clinical and laboratory data. We observed that B10 cell frequencies negatively correlated with CD4
+ lymphocyte frequencies in the peripheral blood of GD patients. This would imply that effecting of CD4 + T lymphocytes are not effectively suppressed by the peripheral tolerance mechanisms of B10 cells, which can result in hyper-proliferation of CD4 + T lymphocytes in GD patients.
IL-10-competence remains the best phenotypic marker for defining human B10 cells. The objective of our study was to determine whether human B10 cells belonged to a distinct subpopulation, or appeared from any B cell population following appropriate activation stimuli. [26] . Based on the observations made in this study, we found that freshly isolated IL-10 + B10 cells from peripheral blood were predominantly found within the CD24 hi and CD27 + B-cell subpopulations. The frequencies of B10 cells were more than 30-fold higher within + B cells in total PBMCs. This phenomenon may be important in the pathogenesis of Graves' disease (GD), but no evidence show that it can be an explanation for the IL-10 independent way. We also assessed the suppressive capacity of purified CD19 + CD24 hi CD27 + B cells on regulated proliferation and cytokine production of CD4 + T cells in healthy individuals. We show that CD19 + CD24 hi CD27 + B cells regulate proliferation of CD4 + T cells through IL-10-independent pathways. Bouaziz et al have also described that purified B cells activated with CpG and anti-immunoglobulins inhibited T-cell proliferation, and this was not reversed following IL-10 blocking. Furthermore, we also found that CD19 +
CD24
hi CD27 + B cells regulates IFN-c production of CD4+T cells through IL-10-dependent pathways and TNF-a production through IL-10 independent pathways. These results were similar to those described by Blair et al, who also stated that the CD24 hi CD27 + B cell subpopulation was able to negatively regulate monocyte cytokine production through IL-10-dependent pathways [22] . IL-10 is known as human cytokine synthesis inhibitory factor (CSIF), and exhibits a very potent anti-inflammatory capacity. Recently, the mechanism of B cells inhibitory capacity has focused on their ability to produce IL-10, and have convincingly demonstrated that B cells producing IL-10 can limit disease in animal models of experimental autoimmune encephalomyelitis, inflammatory bowel disease, and rheumatoid arthritis. However, it has also been reported that B cells can inhibit disease in an IL-10-independent manner [31] . One possible IL-10-independent mechanism of B cell regulation of autoimmune diseases is via the production of antibodies. IgG is reported to bind to inhibitory FcRIIB which is widely expressed by dendritic cells (DCs) and suppresses immune responses through the activation of an ITIM [32, 33] . IgA and IgM produced by activated B cells and plasma cells in the walls of the gastrointestinal and respiratory tracts can be actively transported across epithelial cells into the lumens of these tracts, and perform antimicrobiota functions that can protect against colitis or lung injury [34] . However, as we mentiond before, Graves' disease (GD) is an organ-specific autoimmune disorder characterized by the appearance of pathogenic autoantibodies against thyroid peroxidase (TPO), thyroglobulin (Tg), and the TSH receptor (TSHR). These autoantibodies-TPOAb, TGAb and TSHRAb are belonging to the immunoglobulin G(IgG) subclass [35] . Thus, antibodies were confirmed as having a pathogenic role in GD, so we suggest they probably do not have a protective role in this disease. The other possible mechanism is via the induction of regulatory T cells (Tregs) [36, 37, 38] . We detected CD4 + CD25 + CD127 2 Foxp3 + Treg cells in both healthy individuals and patients, and observed a trend for decreased Tregs in GD patients (Fig. S2) . Since patient samples were limited, we could not perform in vitro coculture experiments. Although we have no explanation as to why Tregs in the patient samples were decreased, it may be related to the B cell suppressive role, but further experiments are required to confirm this point. From in vitro and adoptive transfer experiments, B cells have been shown to have suppressive properties by interacting with T cells and DCs and inducing the production of TGF-b or the promoting costimulatory molecule CD40/CD40L and CD28/ B7 signaling [21, 39, 40, 41, 42] . However, we did not detect the expression of TGF-b or find any difference in B cell-induced suppressive in vitro experiments, when we used inhibitors of CD40 or B7 (data not shown), which is consistent with previous studies [36] . In summary, we think the most likely IL-10-independent mechanism is the proliferation and migration of Tregs induced by B cells.
Our reported findings demonstrate that the suppressive function of the CD24 hi CD27 + B cell subpopulation on CD4 + T cell proliferation and cytokine production was impaired in new-onset and recovered GD patients. It has been previously found that B cell regulation of T cell proliferation is impaired in patients with SLE [21, 43] , but unaffected in patients with RA and pSS [43] . Another notable finding was that although the frequencies of regulatory B cells from peripheral blood were normal from recovered GD patients,CD19
+ CD24 hi CD27 + B cells from recovered patients produced less IL-10 and their suppressive capacity was impaired when compared with healthy individuals. Accordingly, a breakdown of regulatory B cell immunosuppressive functions on proliferation and pro-inflammatory cytokine production in CD4 + T cells may be responsible for GD pathogenesis. Incomplete recuperation from these immunosuppressive functions in recovered GD patient may lead to a GD relapse.
In conclusion, our current findings provide new data that define the phenotype and suppressive capacity of B10 cells from the peripheral blood of healthy individuals and GD patients. Presently, our data are insufficient to determine whether a deficiency in the numbers of B10 and CD19
+
CD24
hi CD27 + cells is the cause of GD, as opposed to an effect of GD. It will be necessary to perform additional studies to fully elucidate the complex role of B10 cells in the pathogenesis and treatment process of GD. Increasing the quantity and improving the function of B10 cells might result in innovative B cell-based therapies for the treatment of GD.
Materials and Methods
Patients and Controls
Peripheral blood was obtained from 15 new-onset (mean, 39 years; range, 23-58 years) and 19 recovered GD patients (mean, 36 years; range, 22-52 years). Diagnosis was established by commonly accepted clinical and laboratory criteria for GD [44] . All new-onset GD patients had not received any anti-thyroid drug treatment, and all GD recovered patients were in a euthyroid state as a result of treatment with methimazole for at least 12 months. Exclusion criteria were: patients with a recent history of infection or evidence of tumor; patients on immunomodulatory drugs; and pregnancy within the last 12 months. Tables 1 and 2 summarize the characteristics of GD patients. Age-matched healthy individuals (n = 36; mean, 37 years; range, 21-54 years) were studied in parallel as controls. The medical ethics council of Shanghai Fifth People's Hospital approved this study (Approval number 002, 2011); patients and healthy volunteers recruited in this study all provided informed consents.
Cell Isolation
Peripheral blood mononuclear cells (PBMCs) were isolated using discontinuous Lymphoprep (Axis-Shield PoC As, Oslo, Norway) gradient centrifugation. Isolated PBMCs were resuspended in phosphate-buffered saline (PBS) containing 2% fetal bovine serum (FBS). 
Flow Cytometry
Cells obtained from healthy individuals, new-onset and recovered GD patients were incubated with normal mouse serum (eBioscience) before staining with a specific antibody. The following antibodies were used for surface staining: FITCconjugated anti-CD4; PE-conjugated anti-CD8; PE-conjugated anti-CD16; FITC-conjugated anti-CD56; FITC-conjugated anti-CD24; PerCP/Cy5.5-conjugated anti-CD19; APC/cy7-conjugated anti-CD27; FITC-conjugated anti-CD4; PE-conjugated anti-CD127; APC-conjugated anti-CD25; Intracellular cytokine analysis by flow cytometry was conducted as previously described [22] .
For IL-10 detection, isolated leukocytes or purified cells were resuspended (1610 6 cells/ml) with 10 mg/ml CpG ODN2006 (Invivogen), 50 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma), 1 mg/ml ionomycin (Sigma), and 16brefeldin A (BFA; BioLegend) for 5 h. Fc receptors were blocked with normal mouse serum before cell surface staining. The following antibodies were used for surface staining: FITC-conjugated anti-CD5, -CD24 or -CD138; PE-conjugated anti-CD1d or -CD10; PerCP/Cy5.5-conjugated anti-CD19; PE/Cy7-conjugated anti-IgD or -CD38; APC-conjugated anti CD20; APC/Cy7-conjugated anti-CD27; and Pacific blue-conjugated anti-IgM or -CD40. Cells were fixed and permeabilized according to the manufacturer's instructions. Permeabilized cells were stained with PE-or APC-conjugated IL-10 monoclonal antibodies. For Foxp3 detection, Pacific blueconjugated anti-Fopx3 was used, and cells were fixed and permeabilized according to the manufacturer's instructions. For IFN-c and TNF-a detection, cells were resuspended (1610 6 cells/ ml) with 50 ng/ml PMA, 500 ng/ml ionomycin, and 16BFA for 6 h. The Fc receptors were blocked with normal mouse serum before cell surface staining. The FITC-conjugated anti-CD4 antibody was used for surface staining. Cell were fixed and permeabilized according to the manufacturer's instructions. Permeabilized cells were stained with an APC-conjugated TNFa monoclonal antibody or Pacific blue-conjugated IFN-c.
Il10 Transcript Expression
CD19
+ B cells were isolated from PBMCs using a Moflo FACS sorter with purities of 95-98%. Total RNA was isolated from purified cells using spin columns (Applied Biosystems, Foster City, CA). Total RNA from each sample was reverse transcribed into cDNA. The expression of IL-10 mRNA was analyzed using quantitative real-time polymerase chain reaction (PCR) methods according to the manufacturer's instructions (Applied Biosystems). The sense GAPDH primer was 59-GCC ACC CAG AAG ACT GTG GAT GGC-39 and the antisense primer was 59-CAT GTA GGC CAT GAG GTC CAC CAC-39. The sense IL-10 primer was 59-CTT CGA GAT CTC CGA GAT GCC TTC-39 and the antisense primer was 59-ATT CTT CAC CTG CTC CAC GGC CTT-39.
Cell Sorting and in vitro Cell Functional Assays
Isolated PBMCs were incubated with normal mouse serum before staining with a specific antibody. We used FITC-CD24, PerCP/Cy5.5-CD19, and APC Cy7-CD27 or FITC-CD4 for surface staining. The CD19 +
CD24
hi CD27 + B cells and CD4 + T cells were isolated using a Moflo FACS sorter (ADP Analyzer; Beckman Coulter) with purities of 90-95%. After purification, CD4
+ T cells were co-cultured with CD19 + CD24 hi CD27 + B cells in the presence of 10 mg/ml CpG, 1 mg/ml CD40L (R&D) and 1 mg/ml anti-CD3. Cells were cultured in 96-well plates for 5 days in complete RPMI 1640 (Gibco) containing 10% FBS, 2 mM Lglutamine, 0.05 mM 2-mercaptoethanol, and 100 U/ml of penicillin and streptomycin. Ionomycin, PMA and BFA were added for the last 6 hours as described previously [21] . Cells were then harvested and CD4 + IFN-c + or CD4 + TNF-a + cells were detected by flow cytometry. For T cell proliferation analysis, BrdU was added for the last 5 hours and detected according to the manufacturer's instructions for the BrdU ELISA colorimetric assay (Roche).
Statistical Analysis
All statistical analysis was performed by Prism 5.0. Results were expressed as mean6SEM. The unpaired two-tailed Student t test for two data sets, or one-way ANOVA for three or more data sets, and the Spearman correlation to evaluate the relationship with B10 cells, CD19
+ B cells and other immunocytes. P values,0.05 were considered statistically significant. Author Contributions
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